etabolic syndrome (MS) is a cluster of multiple atherosclerotic risk factors including glucose intolerance, dyslipidemia, hypertension and visceral obesity. 1 Results from a large population-based study demonstrated that the presence of MS is associated with a high risk of all-cause mortality and cardiovascular morbidity and mortality, regardless of variations in definition of MS. 2, 3 Dyslipidemia in MS is characterized by an increase in triglyceride levels and decrease in high-density lipoprotein (HDL)-cholesterol (C) levels. 4 Despite the fact that lowdensity lipoprotein (LDL)-C is a sensitive indicator of risk for developing cardiovascular disease (CVD) in the general population and the primary target of lipid-modulating therapy, 5 LDL-C is not included in any of the criteria for MS. 1 To date, a useful and convenient method of predicting CVD in individuals with MS has not been established.
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Because the synthesis and degradation of lipoproteins are dependent on insulin action, it has been suggested that the size and composition of lipoproteins are related to insulin resistance, a hallmark of MS. Small dense LDL (sd-LDL) particles stay in the blood for longer and are more susceptible to oxidative modification than medium-sized or large LDL particles. 6 Therefore, sd-LDL particles are easily oxidized and engulfed by macrophages through injured endothelial cells, resulting in the formation of atherosclerotic lesions. 7 In clinically healthy middle-aged men in the general population, previous studies have demonstrated that MS is associated with not only a decrease in adiponectin levels and increase in intima-media thickness of carotid arteries but also a reduction of LDL particle size. 8, 9 However, there has been no cross-sectional or longitudinal study that precisely analyzes correlations of sd-LDL with MS variables. Furthermore, the small size of the LDL particle does not always accompany an increase in sd-LDL mass. 10 It has been suggested that the amount of sd-LDL-C serves as a more sensitive predictor of CVD than LDL-particle size. 10 Therefore, we investigated the actual quantities of sd-LDL-C in patients with MS and their association with MS variables. The present study has examined circulating levels of sd-LDL-C in outpatients in our hospital and the association of these levels with various parameters of MS, including levels of adipocyte-derived cytokines (adipocytokines). Furthermore, we examined the effects of a long period of weight reduction therapy through diet and exercise on these levels in obese patients.
Methods

Subjects
A total of 214 patients (97 men and 117 women, mean age 55.5 years) in our outpatient clinics for adult lifestyle diseases were enrolled during the period from January 2005 to January 2006. All patients had one or more risk factors: hypertension; dyslipidemia (increase in triglyceride and/or decrease in HDL-C); and glucose intolerance. None of the patients had unstable angina, a history of previous myocardial infarction or congestive heart failure. Among 214 patients, there were 169 hypertensive patients, 80 diabetic patients and 117 dyslipidemia patients. They were classified as having or not having MS (non-MS) according to the definition and diagnostic criteria of MS proposed by the Japan Metabolic Syndrome Criteria Study Group in 2005. 11 MS is defined as the presence of central adiposity (waist circumference of ≥85 cm for men and ≥90 cm for women) plus 2 or more of the following 3 criteria: (1) raised concentration of triglyceride, ≥150 mg/dl or reduced concentration of HDL-C, <40 mg/dl; (2) raised blood pressure: systolic blood pressure (SBP), ≥130 mmHg or diastolic blood pressure (DBP), ≥85 mmHg or treatment of previously diagnosed hypertension; and (3) raised fasting plasma glucose concentration, ≥110 mg/dl.
The present study was conducted after the study protocol was approved by the ethical committee on human research at Kyoto Medical Center, and all participants gave written informed consent.
Data Collection
Height and weight were measured, and body mass index (BMI) was calculated as weight in kilograms divided by the square of height in meters as an index of obesity. Waist circumference was measured at the level of the umbilicus in the standing position. SBP and DBP were measured twice with an automatic electronic sphygmomanometer (BP-103i II; Nippon Colin, Komaki, Japan). Blood was taken from the antecubital vein the morning after a 12-h fast to determine fasting plasma glucose, hemoglobin A1c (HbA1c), immunoreactive insulin, total cholesterol (TC), LDL-C, HDL-C, sd-LDL-C, triglyceride, leptin and adiponectin levels. Fasting blood samples were centrifuged within 1 h of collection. Fasting plasma glucose, HbA1c, TC, LDL-C, HDL-C and triglyceride levels were measured according to standard procedures. Immunoreactive insulin was measured by enzyme immunoassay using a commercially available kit (Tosoh, Tokyo, Japan). The insulin resistance index was calculated using homeostasis model assessment (HOMA-R). 12 Profiles in serum lipoprotein subfractions were analyzed using a dual detection HPLC system with 2 tandem connected TSKgel LopapropakXL columns (Skylight Biotech Inc, Akita, Japan) and a LipoPrint LDL system (uantimetrix Corp, Redondo Beach, CA, USA). 13, 14 Mean LDL particle size in the dual detection HPLC system was determined by integrating the mean particle size in each LDL subclass. In the LipoPrint LDL system, LDL-C was separated into 7 subfractions according to size, from LDL1 to LDL7, using polyacrylamide gel tube electrophoresis. The interval from LDL3 to LDL7 was defined as sd-LDL-C. 15 Plasma concentrations of adiponectin and leptin were determined using radioimmunoassay kits (Linco Research, St. Charles, MO, USA). 12 
Weight Reduction Therapy
Among the patients enrolled in this study, 22 obese patients (BMI >28, 8 men and 14 women, mean age 49.7 years) received weight reduction classes at our hospital over 12 months. All patients undergoing weight reduction therapy were instructed to maintain the same levels of energy intake and physical activity for the entire period, as recommended by the Japan Atherosclerosis Society's Guidelines for the Diagnosis and Treatment of Atherosclerotic Cardiovascular Diseases. 16 Diet therapy consisted of 25 kcal/kg of ideal body weight per day. They consumed 60% of total energy as carbohydrate, 20-25% as fat and 15-20% as protein. They were also instructed to exercise more than 30 min at moderate intensity for at least 3 days/week. 12 To check adherence to the instructions on diet and exercise, we monitored their diet and exercise records and measured body weight, HbA1c, TC, LDL-C, HDL-C and triglyceride levels every month. They did not change their smoking habits and prescribed drugs. We defined patients who were able to reduce their body weight by more than 5% as successful in weight reduction, and those who reduced their body weight less than 5% as unsuccessful. These unsuccessful patients did not follow our guidance for diet and exercise therapy while they took our classes.
Statistical Analysis
Data are presented as the mean ± SE, and p<0.05 was considered statistically significant. A student's 2-tailed t-test was used for baseline comparison between non-MS and MS groups (Tables 1 and 2 ). Pearson's correlation coefficients were used to investigate the correlation of TC, LDL-C, sd-LDL-C and sd-LDL-C/LDL-C with metabolic parameters (Tables 3 and 4) , including adiponectin levels (Figs 1A,B and C). Mean levels of sd-LDL-C, sd-LDL-C/LDL-C and LDL-C were stratified by the number of components of MS using ANOVA and Tukey-Kramer post hoc test (Figs 2A,B and C). A stepwise multivariate regression analysis was performed to elucidate factors related to the adiponectin levels in all subjects ( Table 5 ). The following variables were assessed: age; BMI; waist circumference; DBP; and levels of fasting plasma glucose, triglyceride, HDL-C, LDL-C, sd-LDL-C and sd-LDL-C/LDL-C. A 2-way repeated measures ANOVA was performed to compare changes of LDL-C, sd-LDL-C or sd-LDL-C/LDL-C between the successful and unsuccessful patients in weight reduction therapy over 12 months (Figs 3A,B and C). All statistical analyses were performed using Stat View version 5.0 for Windows (SAS Institute Inc). Table 1 summarizes the characteristics of the study cohort, contrasting participants with and without MS. The prevalence of MS among the patients in the present study was 47% according to the criteria proposed by the Japan Metabolic Syndrome Criteria Study Group (Table 1 ). There were 113 and 101 hypertensive patients; 18 and 62 diabetic patients; and 32 and 85 patients with dyslipidemia in non-MS and MS groups, respectively. Calcium antagonists were used in 34 and 38 patients and angiotensin II receptor antagonists were used in 26 and 36 patients in non-MS and MS groups, respectively. Sulfonylureas were used in 2 and 26 patients in non-MS and MS groups, and -glucosidase inhibitors were used in 3 and 16 patients in non-MS and MS groups, respectively. Statins were used in 9 and 31 patients in non-MS and MS groups, respectively. None of the patients of the present study received angiotensin converting enzyme inhibitors, fibrates, insulin sensitizing agents such as thiazolidinediones or insulin therapy.
Results
Clinical Characteristics of Participants With and Without MS
MS was associated with obesity (increase in BMI and waist circumference), insulin resistance (increase in fasting plasma glucose, HbA1c, immunoreactive insulin and HOMA-R) and dyslipidemia (high triglyceride levels and low HDL-C levels) ( Table 1 ). Leptin levels were higher and adiponectin levels were lower in MS patients than non-MS patients. There were no significant differences in TC and LDL-C levels in patients with MS and those without. We determined sd-LDL-C levels using a dual detection HPLC system and a LipoPrint LDL system approved by the US Food and Drug Administration. There was a close relationship between the levels determined with these 2 methods (r=0.634, p<0.001). Therefore, we have utilized the results obtained with the dual detection HPLC system, a simpler and more convenient method. When we analyzed the data separately in men and in women (Table 2) , TC levels were similar between MS and non-MS in both men and women. While LDL-C levels were higher in MS than non-MS in women, these levels were similar between MS and non-MS in men. However, serum levels of sd-LDL-C were significantly higher in the patients with MS than those without in both men and women. Therefore, the ratio sd-LDL-C/LDL-C was signifi- cantly higher in MS than non-MS in both sexes ( Table 2 ). The average size of LDL-C particles was significantly smaller in MS patients than non-MS patients (p<0.01) ( Tables 1 and 2 ).
Correlation Between Traits of MS and LDL-C Profiles
As shown in Table 3 , a linear regression analysis in 214 patients demonstrated that the LDL-C level, sd-LDL-C level, and ratio sd-LDL-C/LDL-C had a significant relationship to age, severity of obesity (BMI and waist circumference), DBP, insulin resistance (fasting plasma glucose, immunoreactive insulin and HOMA-R), triglyceride and adiponectin. The ratio sd-LDL-C/LDL-C but not the LDL-C or sd-LDL-C level had a significant relationship with an increase in HbA1c and decrease in HDL-C levels. We also performed the analysis separately in men and women (Table 4 ). The levels of sd-LDL-C and sd-LDL-C/LDL-C were significantly correlated with waist circumference in men, but not women. In contrast, the sd-LDL-C level was correlated with impaired glucose tolerance (fasting plasma glucose, HbA1c, immunoreactive insulin, and HOMA-R) in women, but not in men. Among the correlations of sd-LDL-C or sd-LDL-C/LDL-C levels with MS variables, the relationship between the increase in the ratio sd-LDL-C/LDL-C and decrease in the adiponectin level was the strongest in both men and women. The adiponectin level was more closely associated with the value of the ratio sd-LDL-C/LDL-C than that of the LDL-C or sd-LDL-C level ( Figs 1A,B and  C) .
We examined the levels of sd-LDL-C and LDL-C and the ratio sd-LDL-C/LDL-C stratified by the number of risk factors for MS. As shown in Figs 2A ,B and C, the higher the number of risk factors, the higher the levels of sd-LDL-C and the ratio sd-LDL-C/LDL-C. However, the levels of LDL-C were not affected. Among these parameters, the correlation with the incidence of risk factors was most pronounced for sd-LDL-C/LDL-C (p<0.001).
In addition, the relative contribution of each MS component, LDL-C, sd-LDL-C and the ratio sd-LDL-C/LDL-C to the adiponection level was examined in a stepwise multivariate linear regression analysis ( Table 5 ). The variables independently associated with the adiponectin level were age, HDL-C and ratio sd-LDL-C/LDL-C. Among these variables, the increase in the ratio sd-LDL-C/LDL-C was the strongest independent variable that contributed to the decreased adiponectin level ( =-0.460, p<0.001). Abbreviations see in Table 1 . Table 1 .
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Fig 1. Correlations between serum low-density lipoprotein-cholesterol (LDL-C) (A), small dense-LDL-C (sd-LDL-C) (B)
, or sd-LDL-C/LDL-C level (C) and serum adiponectin level. 
Effects of Body Weight Reduction on sd-LDL-C Levels and the Ratio sd-LDL-C/LDL-C
We examined serial changes in lipid profiles during a 1-year follow-up of weight reduction therapy involving diet and exercise in patients with a BMI >28 in our weight reduction classes. During this therapy, anti-hypertensive, diabetic and anti-hyperlipidemic agents were unchanged. Among 22 patients who participated in our classes, 11 patients maintained our therapy and were able to reduce their body weight by more than 5%. In these patients, BMI, waist circumference, SBP and DBP and triglyceride levels significantly decreased by 4.9%, 7.7%, 16.5%, 10.9% and 10.7%, respectively, and adiponectin levels significantly increased by 19.0%. LDL-C levels decreased at one month after the start of diet and exercise, but were constant thereafter (Fig 3A) . In contrast, sd-LDL-C levels decreased more gradually than LDL-C levels (Fig 3B) . At 12 months after the start of this therapy, however, the percent decrease was greater in sd-LDL-C (15.0%) than LDL-C (10.8%) levels. Therefore, the ratio sd-LDL-C/LDL-C did not decrease at one or 6 months after the start but significantly decreased at 12 months (Fig 3C) . On the other hand, the remaining 11 patients who did not maintain therapy were not able to reduce their body weight. In these patients, sd-LDL-C and LDL-C levels did not decrease and the ratio sd-LDL-C/ LDL-C was constant throughout the period. By repeated measures ANOVA, levels of sd-LDL-C but not those of LDL-C significantly declined only in patients successful in weight reduction (p=0.039). Furthermore, the decrease in sd-LDL-C/LDL-C strongly correlated with the increase in the adiponectin level through weight reduction (r=-0.477, p=0.044).
Discussion
To determine LDL-C subclasses, previous studies have utilized conventional methods such as density gradient ultracentrifugation nondenaturing gradient gel electrophoresis and nuclear magnetic resonance spectroscopy. [17] [18] [19] [20] However, these methods are labor-intensive, expensive and require skill and experience as well as a lot of time. With the dual detection HPLC system employed in the present study, sd-LDL-C levels are determined in a semiautomatic mode with high reproducibility, in only 1 h, in addition to providing information on heterogeneity, VLDL and HDL as well as LDL. 21, 22 The sd-LDL-C levels determined with this system are closely correlated with those levels obtained using the LipoPrint LDL system approved by the US Food and Drug Administration. 14 These findings suggest that the dual detection HPLC system is convenient and useful for determining sd-LDL-C levels in ordinary clinical medicine.
The present study has compared lipid profiles between patients with MS and those without MS. Because we recruited subjects from our outpatient clinics for adult lifestyle diseases, MS-related variables such as blood pressure and insulin resistance were relatively high even in non-MS patients. Nevertheless, sd-LDL-C levels were significantly higher in MS than non-MS, while LDL-C levels were simi- Abbreviations see in Table 1 . lar between MS and non-MS in both men and women. Our findings are consistent with the report by Gazi et al also showing that cholesterol concentrations in sd-LDL particles were higher in MS patients than control subjects. 23 We noted several sex-related differences in the relationship of the sd-LDL-C level with MS variables. In contrast to men, there was no significant relationship of the sd-LDL-C level with waist circumference in women. This may be attributable to that increased waist circumference in women reflect increased amount of subcutaneous fat as well as that of visceral fat. Interestingly, the increase in the sd-LDL-C level was significantly correlated with impaired glucose tolerance in women but not in men. Presumably, this might represent the difference in the pathophysioligical mechanisms of impaired glucose tolerance or hyperlipidemia between men and women. Further studies are needed on precise mechanisms of such sex differences. The present study demonstrated that the amount of sd-LDL-C was predominantly elevated in MS patients. Since sd-LDL is basically a part of LDL, we hypothesized that the ratio sd-LDL-C/LDL-C may serve as a more sensitive marker. We have found that the ratio sd-LDL-C/LDL-C rather than the LDL-C or sd-LDL-C level correlates well with various parameters associated with MS. In addition, we showed that the greater the number of risk factors for MS, the higher the ratio, despite LDL-C staying constant. These findings suggest that sd-LDL-C/LDL-C provides a more useful clinical indicator of the pathophysiological state of MS patients than the LDL-C or sd-LDL-C level. A stepwise multiple regression analysis revealed that the most important factor determining the decreased level of adiponectin, an anti-atherogenic and anti-inflammatory adipocytokine, was the increased ratio of sd-LDL-C/LDL-C. However, the cause and effect relationship between the adiponection level and the ratio sd-LDL-C/LDL-C remains to be elucidated. 24 Interestingly, Jang et al reported that the presence of a G allele in the adiponectin gene at SNP 276 is correlated with greater oxidative stress, higher sd-LDL-C concentrations and smaller LDL particle size. 25 One of the mechanisms that link hypoadiponectinemia with the increase in the ratio sd-LDL-C/LDL-C might be insulin resistance caused by low adiponectin levels in MS patients. Further studies are needed to elucidate precise mechanisms of their linkage in patients with MS.
Subjects in the present study included those taking statins, which directly affect lipid metabolism, as well as angiotensin II receptor antagonists, sulfonylureas, orglucosidase inhibitors, which may affect insulin resistance and adiponectin levels. We also analyzed all the data of 115 patients by excluding 99 patients taking these agents. Similar to the results yielded by including these patients, the levels of sd-LDL-C and sd-LDL-C/LDL-C were higher in patients with MS than those without. Furthermore, the sd-LDL-C/LDL-C level was the strongest independent determinant of hypoadiponectinemia. Therefore, the tight connection of sd-LDL-C/LDL-C with adiponectin is independent of effects by these agents.
Although previous papers described the effects of weight reduction therapy on LDL profiles for a short period, a full year follow-up study has not been performed. [26] [27] [28] Interestingly, in the present study, while the LDL-C levels dropped rapidly, the sd-LDL-C levels decreased more gradually. This may be attributable to sd-LDL-C staying in the blood stream longer than LDL-C. In contrast to our finding that the ratio sd-LDL-C/LDL-C did not decrease at 1 month after the start of diet and exercise, Yoshino et al reported that LDL particle size increased one month after weight reduction therapy. 28 This discrepancy may be in part attributable to the fact that they used mazindol, a catecholamine re-uptake inhibitor, for weight reduction, whereas we exclusively used diet and exercise without any drug treatment. However, in our patients who successfully lost weight, sd-LDL-C levels had decreased more than LDL-C levels at 1 year after the start of the diet and exercise program. Furthermore, the decrease in sd-LDL-C/LDL-C strongly correlated with the increase in the adiponectin level. It has been reported that mean LDL particle size was increased by treatment with atrovastatin and decreased by treatment with pravastatin in patients with familial hyperlipidemia. 29 Recently, we reported that highly purified eicosapentaenoic acid reduced levels of sd-LDL-C, detected with a LipoPrint LDL system, remnants and CRP in patients with MS. 30 There is a need to further discuss the best use of diet, exercise and various pharmacological agents to reduce the risk of CVD in patients with MS.
The Japanese and NCEP guidelines for MS emphasize, in addition to the importance of cholesterol control, the importance of other risk factors for prevention of CVD. 31 The present study demonstrates that the ratio sd-LDL-C/LDL-C provides a sensitive marker that represents the pathophysiological state of MS. It has been reported that the amount of sd-LDL-C is an accurate predictor of CVD. Therefore, the results of the present study may also explain the reason why CVD incidence is higher in patients with MS than those without, despite similar levels of LDL-C between MS and non-MS. Measuring amounts of sd-LDL-C is much simpler with the dual detection HPLC system than with other methods. Therefore, the determination of the ratio sd-LDL-C/LDL-C by the HPLC system may be useful for assessing and managing MS patients.
